Nkarta (NKTX) Amortizatization of Intangibles (2020 - 2026)
Nkarta (NKTX) posted quarterly Amortizatization of Intangibles of $753000.0 for Q1 2026, down 51.88% year-over-year from $1.6 million in Q1 2025, and down 11.93% quarter-over-quarter from $855000.0 in Q4 2025.
Nkarta (NKTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Nkarta's Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $753000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 51.88% year-over-year to $753000.0; the TTM figure through Mar 2026 stood at $3.8 million (down 45.46% YoY), while the FY2025 annual figure was $4.6 million, down 33.74% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $753000.0, down from $855000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $2.4 million in Q3 2023, with the low at -$727000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $1.6 million (2025), against an average of $1.3 million.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles jumped 689.56% in 2023, then slumped 55.79% in 2025.
- Nkarta's Amortizatization of Intangibles stood at $1.6 million in 2022, then gained by 28.08% to $2.0 million in 2023, then slipped by 4.49% to $1.9 million in 2024, then slumped by 55.79% to $855000.0 in 2025, then fell by 11.93% to $753000.0 in 2026.
- Business Quant data shows NKTX's Amortizatization of Intangibles at $753000.0 in Q1 2026, $855000.0 in Q4 2025, and $953000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 464,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 464,000.00 |
| Jun 30, 2026 | 464,000.00 |
| Mar 31, 2026 | 753,000.00 |
| Mar 31, 2026 | 753,000.00 |
| Dec 31, 2025 | 855,000.00 |
| Dec 31, 2025 | 855,000.00 |
| Sep 30, 2025 | 953,000.00 |
| Sep 30, 2025 | 953,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.96 Mn |
| Sep 30, 2024 | 1.96 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.57 Mn |